Anastrozole is a vital part of breast cancer treatment, especially for hormone receptor-positive breast cancer in postmenopausal women. As a powerful aromatase inhibitor, it efficiently inhibits the conversion of androgens to estrogens, reducing estrogen synthesis and hence stimulating the growth of hormone receptor-positive breast cancers. By lowering estrogen levels, anastrozole slows or stops the progression of the disease and prevents recurrence. Anastrozole is commonly provided orally as additional treatment after surgery or as part of metastatic breast cancer treatment procedures. Individualized dose is set based on patient parameters such as age, menopausal state, and overall health, with bone health and lipid levels monitored regularly to prevent side effects. Anastrozole is the basis in the treatment of hormone receptor-positive breast cancer.